Why BGPT?
logo

Author profiles with data insight

Track an author's datasets, methods, and reproducibility signals across their papers with direct citations.







Press Enter ↡ to solve



    Fuel Your Discoveries




     Quick Explanation


    BGPT evidence-grounded audit (A.V.R): key red/green flags
    • Strong (example primary clinical dataset): magnetic-bead extraction showed higher HPV detection and stronger hemoglobin robustness in a large sample analysis (combined 2,445/16,540 positives; retrospective 11.43% vs prospective 17.58%; hemoglobin tolerance up to 60 g/L).
    • Weak/uncertain: several items in the provided β€œA.V.R” bundle are narrative reviews (not new data), so β€œevidence extraction” strength depends heavily on whether the author distinguishes preclinical vs clinical, standardizes methods, and guards against selection bias.
    Run the AI Scientist agent to re-audit, tabulate, and consistency-check the full extracted evidence set end-to-end.



     Long Explanation


    A.V.R β€œfull-text audit / DOI lookup / evidence extraction” β€” evidence-grounded scientific strength review
    Because only extracted bibliographic+evidence fields (not the author’s full text audit/report itself) were provided, this review evaluates scientific strength of the underlying evidence bundle you supplied, and highlights where such an audit would be strong vs where it would likely be weak/biased. All numerical statements below are tied to the supplied extracted fields for the cited DOIs.
    1) Visual evidence snapshots (from the provided extracted data)
    HPV extraction: detection gain & hemoglobin robustness
    HPV extraction: overall longitudinal positives (retrospective vs prospective)
    HPV extraction: reported hemoglobin interference threshold
    HPV extraction: cost vs detection-rate uplift (reported)
    2) Scientific strength assessment of the β€œevidence extraction bundle” you provided
    2.1 Primary clinical-style evidence (best case for an audit)
    • The HPV extraction paper includes both small paired analysis (n=639) and large longitudinal comparisons totaling 16,540 samples, enabling separation of β€œwithin-pair method effect” from broader dataset-level behavior.
    • It reports explicit inhibitor challenges using hemoglobin spiking series, and quantifies performance change (including Kappa agreement and genotype yield differences in the small study).
    2.2 Where an β€œaudit/evidence extraction” often becomes weak
    • Multiple provided items are narrative reviews (no new datasets generated). An audit can still be useful, but the scientific strength hinges on whether the author performed systematic search, standardized extraction, and guarded against selection/publication bias.
    • When evidence is heterogeneous (e.g., varying extraction methods, plant chemotypes, or assay conditions), an audit must distinguish β€œsignal robust across protocols” vs β€œeffects depend on preparation.” This heterogeneity is explicitly emphasized in several provided review summaries (EO composition variability; cereal phytochemical extraction method variability).
    2.3 Specific methodological blindspots an auditor should check (and likely will)
    • Inhibitor scope: the HPV paper’s limitation notes focus on hemoglobin only (other inhibitors not evaluated). This means the β€œrobustness” claim may not extend to other common PCR inhibitors.
    • Population comparability: retrospective vs prospective phases can have different case mixes. An audit should test for confounding by population differences rather than attributing changes solely to extraction.
    • Quality-control/reporting transparency (applies to narrative reviews): an auditor should verify whether the review used explicit protocol elements (e.g., PRISMA, preregistration, inclusion/exclusion criteria). In the provided EO and cannabis narrative reviews, systematic-level details are not guaranteed to match best practices; thus strength is often β€œreview utility” rather than β€œevidence certainty.”
    3) Cross-paper quantitative snapshot (from provided per-paper scoring fields)
    Below is a compact view of the provided per-paper scientific quality / reproducibility / usefulness scores, showing where the audit bundle is likely strongest vs weakest. (These scores are taken from your extracted fields; an actual author audit would confirm them against the original papers.)
    4) Scientific-credibility critique: what would strengthen or weaken β€œA.V.R” specifically
    • Strength to aim for: if the audit extracted effect sizes, uncertainty (CIs/p-values), sample provenance (retrospective vs prospective), and inhibitor scope, it would be closer to an evidence-based synthesis. The HPV extraction item models this style (positive rates, thresholds, cost tradeoff, and explicit limitations).
    • Weakness red flag: narrative reviews without systematic methodology risk over-weighting favorable findings and under-weighting failures. This risk is explicitly acknowledged in multiple provided review summaries (heterogeneity, standardization barriers, limited in vivo/clinical evidence).
    What would most likely change the conclusions
    • If broader studies tested additional PCR inhibitors beyond hemoglobin, the generalization of the extraction advantage could be reduced or reversed.
    • If retrospective/prospective population differences (and assay-platform differences, if any) explained part of the longitudinal detection-rate changes, the extraction-only attribution would weaken.
    • For review-heavy bundles, systematic evidence mapping (instead of narrative synthesis) could change the ranking of which claims are well-supported vs speculative.


    Feedback:    

    Updated: April 20, 2026

     Top Data Sources ExportMCP


     Analysis Wizard



    It will parse the extracted numeric fields (HPV rates, Hb thresholds, cost deltas) into structured tables and auto-generate Plotly figures, then consistency-check totals against reported denominators.



     Hypothesis Graveyard


    The claim that β€œEO-loaded nanocarriers generally improve anticancer efficacy” is less explanatory once compositional heterogeneity and inconsistent in vivo endpoints are controlled; the narrative generalization likely reflects selection and reporting bias rather than a universally causal delivery mechanism.


    The suggestion that β€œberberine benefits are largely extraction-independent” is undermined if purity/yield variance materially alters bioactive concentration and exposure-response relationships across studies.

     Science Art


    Author Review: A.V.R full-text audit DOI lookup evidence extraction Science Art

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion








    Get Ahead With Science Insights

    Custom summaries of the latest cutting edge Science research. Every Friday. No Ads.


    My BGPT






     Trending